2020-12-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/683266本科技防疫場域驗證計畫是透過半導體生物感測晶片(Bio-ASIC)技術應用於新型冠狀病毒抗原快速篩檢之產學合作案。本案與永加利團隊開發的快速檢測試劑，並集結先進製程晶片廠＿台積電、醫療量測設備系統廠＿緯創醫學及台灣精密加工產業等台灣優秀廠商所發展以半導體為載基的全新跨領域生物感測技術(場效電晶體生物感測晶; Bio-FET晶片)。此技術突破傳統基於光學生物感測模式的侷限性，將半導體晶片進行表面改質技術，將待測物之標記分子抗體連結於晶片表面，並整合封裝、微流體系統及檢驗流程所需之控制項目於該定點量測設備中，進行電訊號變化計算其抗體抗原結合之濃度，進行分析。該廠商開發之晶片鎖定專一性高的抗原抗體結合之免疫反應，開發可快速(15~30分鐘內)、精準(<1*105 copies/mL)之生醫檢測晶片，並結合臺灣大學跨領域學門的學術研究量能、臺大醫院醫療照護與疫病因應的豐富經驗，以臺灣大學醫學院附設醫院轄下之所有體系醫院為驗證場域，進行檢驗效能(diagnostic performance)驗證，提供不同於傳統核酸抗體檢驗的全新新冠病毒感染診斷工具，以符合實務場域防疫對於即時性診斷工具之多種要求，並用於用於疫病篩檢、臨床診斷、治療評估、感染控制、隔離檢疫等重要的決策依據。供臨床醫療與公衛防治上另一種敏感、準確、迅速、簡易操作、且成本相對低廉的病毒快速檢測法 "In this project, we have achieved the goal through the semiconductor biochip technology. And we integrate the semiconductor chip, specific packaging, microfluidics system and all the central laboratory process into a handheld device for the best diagnostics, include high accuracy, high quality and repeatability on the POC platform device. VSensor breaks through the limitations of traditional optical-based biosensors and delivers lab quality results within 15 minutes. Now, we want to demonstrate our value on COVID-19 with this highly integrated technologies. Effectively reduce TAT for doctor’s better decision and reduce the risk. And the rapid and accurate decision can effectively reduce the cost of medical insurance. So, it can create a win-win situation for patients, doctor, hospital and insurance providers. However, we believe that if there is a POC platform to solve the high expense and high liability problems, and provide a systematic collection of patients` reports to provide doctor to make the major decision of patients."半導體生物感測晶片新型冠狀病毒抗原快速篩檢Coronavirus disease 2019COVID-19ACLMin vitro diagnostic